Crinetics Pharmaceuticals, Inc. (CRNX) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
CRNX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CRNX Revenue Analysis (2016–2025)
As of March 2, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) generated trailing twelve-month (TTM) revenue of $5.4 million. The most recent quarter (Q4 2025) recorded $3.9 million in revenue, up 2616.8% sequentially.
Looking at the longer-term picture, CRNX's 5-year compound annual growth rate (CAGR) stands at +138.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $5.4 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CRNX's business is primarily driven by Product (70%), and License and Service (30%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY). Compare CRNX vs AGIO →
Peer Comparison
Compare CRNX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRNXCurrent | $5M | - | +138.0% | -9534.5% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.4M | +421.7% | $4.3M | 80.1% | $-516,769,000 | -9534.5% |
| 2024 | $1.0M | -74.1% | $1.0M | 100.0% | $-338,854,000 | -32613.5% |
| 2023 | $4.0M | -15.3% | $4.0M | 100.0% | $-222,608,000 | -5547.2% |
| 2022 | $4.7M | +339.4% | $4.7M | 100.0% | $-167,882,000 | -3544.1% |
| 2021 | $1.1M | +1418.3% | $1.1M | 100.0% | $-107,702,000 | -9990.9% |
| 2020 | $71K | -94.0% | $-56,927,000 | -80178.9% | $-74,953,000 | -105567.6% |
| 2019 | $1.2M | -50.9% | $80K | 6.7% | $-53,832,000 | -4512.3% |
| 2018 | $2.4M | +18.7% | $-22,051,000 | -908.2% | $-28,710,000 | -1182.5% |
| 2017 | $2.0M | +247.2% | $-7,188,000 | -351.5% | $-9,127,000 | -446.3% |
| 2016 | $589K | - | $-4,511,000 | -765.9% | $-6,044,000 | -1026.1% |
See CRNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRNX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CRNX vs AGIO
See how CRNX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CRNX's revenue growth accelerating or slowing?
CRNX TTM revenue: $5M. YoY growth: N/A. 5-year CAGR: +138.0%.
What is CRNX's long-term revenue growth rate?
Crinetics Pharmaceuticals, Inc.'s 5-year revenue CAGR of +138.0% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CRNX's revenue distributed by segment?
CRNX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.